Exelixis, a U.S.-based biotech company specializing in cancer treatments, is positioned for market-beating returns through its growing pipeline beyond its blockbuster cabozantinib drug. The company reported 57.9% EPS growth in 2025 and recently received FDA approval for zanzalintinib for metastatic colorectal cancer. With zanzalintinib in four phase 3 trials and strategic partnerships with major pharma companies, Exelixis aims to become a top-five solid tumor oncology company.

Billionaire investor Stanley Druckenmiller holds two major positions in his portfolio: Natera (NTRA), a genetic testing company with strong revenue growth and expanding margins despite current losses, and Taiwan Semiconductor Manufacturing (TSM), which benefits from AI demand but faces challenges with rising capital expenditures that will limit future cash-flow margin expansion.

The global esoteric testing market is projected to grow from $27.52 billion in 2025 to $41.56 billion by 2031 at a 7.11% CAGR, driven by rising chronic disease rates, personalized medicine demand, and liquid biopsy adoption. However, stringent regulatory frameworks and reimbursement pressures pose significant challenges to market expansion.

The global Non-Invasive Prenatal Testing (NIPT) market is projected to grow at a CAGR of 17.01% from 2024 to 2031, reaching USD 9.83 billion from USD 2.8 billion in 2024. Growth is driven by rising demand for early fetal detection, advancements in next-generation sequencing technology, and increased adoption of safer prenatal testing methods. However, high costs, regulatory hurdles, and limited insurance coverage remain significant market restraints, particularly in emerging markets.

The global reproductive genetics market is projected to grow from USD 7.31 billion in 2025 to USD 16.67 billion by 2032, with a CAGR of 12.5%. Growth is driven by rising demand for genetic testing, preimplantation genetic testing (PGT), and non-invasive prenatal testing (NIPT), though ethical and legal challenges continue to limit expansion. North America leads with 40.5% market share, while Asia Pacific is the fastest-growing region.

Natera presented research showing its Signatera Genome test can effectively predict distant recurrence risk in stage II-III breast cancer patients by measuring molecular residual disease (MRD) status after treatment.

Adaptive Biotechnologies' stock dropped after Natera acquired Foresight Diagnostics for $275 million upfront, raising competitive concerns in the blood-cancer minimal residual disease (MRD) market.

Natera acquired Foresight Diagnostics for $275 million upfront with potential additional $175 million in earnouts, strengthening its precision oncology capabilities through advanced circulating tumor DNA testing technology.

Billionaire investor Stanley Druckenmiller has invested 30% of his portfolio in three biotech stocks: Natera, Insmed, and Teva Pharmaceutical Industries, demonstrating strong confidence in the biotech sector's potential.

The global liquid biopsy market is projected to grow from $4.03 billion in 2025 to $7.05 billion by 2030, driven by rising cancer incidence, precision medicine advancements, and technological innovations in early disease detection.

Personalis reported Q2 2025 financial results with revenue falling 24% year-over-year to $17.2 million, missing estimates. Despite financial challenges, the company saw a 59% increase in clinical test volumes for its NeXT Personal platform, with promising cancer detection research.

The U.S. minimal residual disease testing market is projected to reach $2020 million by 2033, growing at a 9.38% CAGR, driven by rising cancer rates and advancements in precision medicine technologies like NGS and flow cytometry.